SCHEMBL1689799

SCHEMBL1689799

CCCCCc1cc(O)cc(-c2ccccc2)c1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS2 P35354 5/20 0.65
CYP3A4 P08684 2/20 0.65
TRPV1 Q8NER1 1/20 0.52
ESR1 P03372 2/20 0.49
ADRA2A P08913 2/20 0.49
ADORA3 P0DMS8 2/20 0.49
TACR2 P21452 2/20 0.49
SLC6A2 P23975 2/20 0.49
SLC6A4 P31645 2/20 0.49
SLC6A3 Q01959 2/20 0.49
KDM4E B2RXH2 1/20 0.49
ALDH1A1 P00352 1/20 0.49
LMNA P02545 1/20 0.49
SHBG P04278 1/20 0.49
TP53 P04637 1/20 0.49
HSPD1 P10809 1/20 0.49
ADRB3 P13945 1/20 0.49
HTR2C P28335 1/20 0.49
HSPE1 P61604 1/20 0.49
HIF1A Q16665 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28164034 0.88 HSD11B1 (0.51) PTGS2CYP3A4TRPV1ALDH1A1
SCHEMBL29843944 0.86 PTGS2 (0.50) PTGS2CYP3A4TRPV1ALDH1A1
SCHEMBL27909193 0.86 PTGS2 (0.50) PTGS2CYP3A4TRPV1ALDH1A1
Cardol SCHEMBL7055167 0.83 PTGS2 (0.79) PTGS2CYP3A4ESR1ADRA2AADORA3
SCHEMBL27407916 0.82 HSD11B1 (0.50) PTGS2CYP3A4TRPV1ALDH1A1HSD17B10
SCHEMBL11513697 0.82 HSD11B1 (0.50) PTGS2CYP3A4TRPV1ALDH1A1HSD17B10
SCHEMBL15823399 0.81 PTGS2 (0.66) PTGS2CYP3A4ESR1ADRA2AADORA3
SCHEMBL91256 0.80 RXRA (0.50) PTGS2CYP3A4ESR1TP53EGFR
While Olivetol SCHEMBL31545864 0.80 PTGS2 (1.00) PTGS2CYP3A4ESR1ADRA2AADORA3
While Olivetol SCHEMBL16922154 0.80 PTGS2 (1.00) PTGS2CYP3A4ESR1ADRA2AADORA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8093385-B2 Leukotriene B4 inhibitors HOFFMANN-LA ROCHE INC. (US) 2012-01-10 US disclosed
EP-2190808-A1 LEUKOTRIENE B4 INHIBITORS F. Hoffmann-Roche AG (CH) 2010-06-02 EP disclosed
WO-2009024492-A1 LEUKOTRIENE B4 INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2009-02-26 WO disclosed
US-20090054466-A1 Leukotriene B4 Inhibitors DOMINIQUE ROMYR 2009-02-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090054466-A1 Leukotriene B4 Inhibitors LTB4R2, LTB4R, LTC4S PTGS2 40/4885CYP3A4 402/4885TRPV1 969/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.